GGrantIndex
Sort

50,496 grants matching lung cancer

Genetic Epidemiology of Lung Cancer

$982,565
Marshall W Anderson · University Of Cincinnati · U01 · FY2009 · CA

Chromatin Remodeling and Gene Activation

$982,543
David J Clark · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2014 · HD

Promoting follow-up of abnormal cancer screening tests using population-basedsystems to support stepped care multilevel intervention

$982,509
Jennifer S Haas · Massachusetts General Hospital · U01 · FY2020 · CA

New Paradigms for Targeting Truncal Driver Mutations

$982,500
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2017 · CA

New Paradigms for Targeting Truncal Driver Mutations

$982,500
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2020 · CA

New Paradigms for Targeting Truncal Driver Mutations

$982,500
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2016 · CA

New Paradigms for Targeting Truncal Driver Mutations

$982,500
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2021 · CA

Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant

$982,488
Brenton Scott · Pulmotect, Inc · R44 · FY2015 · HL

TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT

$982,258
Chinthalapally Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2022 · CA

Development of Natural Product Leads as Anticancer Therapeutics

$981,960
John Beutler · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

2/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)

$981,839
Christina Ciecierski · Northeastern Illinois University · U54 · FY2021 · CA

Next Generation Smart Nanoparticles

$981,050
Paul Alivisatos · Stanford University · U54 · FY2012 · CA

Nanotechnology for Multiplexed and Intraoperative Cancer Detection

$980,999
Shuming Nie · Emory University · RC2 · FY2009 · CA

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs

$980,918
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Molecular Pathology Research for Cancer Diagnostics and Biomarkers

$980,906
Robert Simpson · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA

MIT Center for Environmental Health Sciences

$980,566
John M Essigmann · Massachusetts Institute Of Technology · P30 · FY2017 · ES

PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

$980,392
John Gillespie · 20/20 Genesystems, Inc. · R44 · FY2012 · CA

CORE CENTER FOR GENE THERAPY

$980,282
University Of Washington · P30 · FY2002 · DK

CORE CENTER FOR GENE THERAPY

$980,282
University Of Washington · P30 · FY2001 · DK

CORE CENTER FOR GENE THERAPY

$980,282
University Of Washington · P30 · FY2003 · DK

CORE CENTER FOR GENE THERAPY

$980,282
University Of Washington · P30 · FY2000 · DK

Angiogenesis and Tumor Growth

$980,168
Giovanna Tosato · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA

UNIVERSITY OF TEXAS SPORE IN LUNG CANCER

$980,000
University Of Texas Sw Med Ctr/Dallas · P50 · FY2000 · CA

Missouri Valley Cancer Consortium CCOP

$980,000
Missouri Valley Cancer Consortium, Inc. · U10 · FY2002 · CA

Leveraging Diversity in Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores

$979,999
David V Conti · University Of Southern California · U01 · FY2022 · CA